Table 3.
Immunotherapy in Chondrosarcoma.
| AGENTS | STUDY DESIGN/PHASE | # of PATIENTS | PRIMARY EFFICACY ENDPOINT | REFERENCE |
|---|---|---|---|---|
| NY-ESO-1 specific T Cell Receptor (TCR) T Cell in Sarcoma | Phase I | n=20 | Safety/Efficacy | NCT03462316 |
| LN-145, aldesleukin | Phase II | n=80 | To evaluate efficacy using ORR | NCT03449108 |
| Pembrolizumab (anti PD-1) | Phase II | n=146 | ORR | NCT02301039 |
| Nivolumab plus Ipilimumab (anti PD-1 and anti CTLA4) | Phase II | n=40 | CR and PR | NCT02982486 |
| Toripalimab (anti PD-1) | Phase I | n=258 | Safety/Efficacy | NCT0347640 |
| Nivolumab plus ABI-009 (Nab-rapamycin) | Phase Ib | n=40 | Safety, dose-escalation | NCT03190174 |